Overview
Tirzepatide is an acylated research peptide engineered to activate both GIP and GLP-1 receptors. This separate pre-filled pen format contains 20mg total, divided into four 5mg portions, and is intended for laboratories that need a ready-to-use research format while preserving the same dual-incretin target profile.
Research Reference: View compound profile on NIH PubChem
Research Focus
WHAT THIS FORMULA FEATURES
Dual GIPR/GLP1R receptor activity in a single peptide; an acylated structure designed for extended exposure; and a receptor-signaling profile that is useful for comparing integrated incretin signaling with single-receptor controls.
EXPECTED RESEARCH READOUTS
Typical experimental endpoints include GIPR and GLP1R cAMP signaling, beta-arrestin recruitment, receptor internalization, insulin- and glucagon-related responses in appropriate models, glucose-excursion measurements, and receptor-selective pathway analysis.
Key Characteristics
PRODUCT CONFIGURATION
Total dosage: 20mg
Package: 1 pre-filled research pen
Configuration: 4 × 5mg
Pen color: Dark Orange
RESEARCH PROFILE
Compound profile: Dual GIP / GLP-1 receptor agonist research peptide
Format: Pre-filled research pen
Fulfilment: Fast Stock across local locations + Global shipping
Transit: Cold-chain packed with ice packs
Research use only. Not approved for human or animal use.
